Report from the extraordinary general meeting in Orexo AB, 6 August 2013

The extraordinary general meeting resolved on 6 August on amendment to Performance-based, Long-term Incentive Program 2011/2021, issue of warrants with the right to subscribe for new shares and approval of disposal of the warrants.

For more information regarding the resolutions at the extraordinary general meeting reference is made to the complete proposal which is available on the company’s webpage.

 
For further information, please contact:

Nikolaj Sørensen, President and CEO
Tel: + 46-703 50 78 88, Email: nikolaj.sorensen@orexo.com



 
About Orexo

Orexo is an emerging specialty pharma company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary drug delivery technology. Orexo’s expertise is within the area of reformulation technologies and especially sublingual formulations. The company has a portfolio of revenue-generating US and EU approved products currently marketed under license and a pipeline of several reformulations of approved compounds for areas of unmet medical need. Orexo also has collaboration projects with several international pharmaceutical companies. Orexo, with its headquarters in Sweden, is listed on NASDAQ-OMX. The largest shareholders are Novo A/S and HealthCap.

For information about Orexo AB please visit www.orexo.com .

Orexo is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 16:45 CET on August 6, 2013.


About Us

Orexo develops improved pharmaceuticals based on innovative drug delivery technologies.The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The main market today is the US market for the treatment of opioid dependence where the product Zubsolv® is commercialized by Orexo. Other products are commercialized by license partners, including Zubsolv in markets outside of the US. Total net sales for 2016 amounted to SEK 705.9 million and the number of employees was 102. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) index and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where also research and development is performed, is located in Uppsala, Sweden.

Subscribe

Documents & Links